Sharlene Gill

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8763470/publications.pdf

Version: 2024-02-01

102 papers	4,829 citations	147801 31 h-index	95266 68 g-index
113 all docs	113 docs citations	113 times ranked	6849 citing authors

#	Article	IF	Citations
1	Impact of Tumor Location on Patient Outcomes in Small Bowel Cancers. Clinical Colorectal Cancer, 2022, 21, 107-113.	2.3	2
2	Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. Journal of Clinical Oncology, 2022, 40, 892-910.	1.6	85
3	Early-Age-Onset Colorectal Cancer in Canada: Evidence, Issues and Calls to Action. Current Oncology, 2022, 29, 3149-3159.	2.2	4
4	Trends in the incidence of young-onset colorectal cancer with a focus on years approaching screening age: A population-based longitudinal study. Journal of the National Cancer Institute, 2021, 113, 863-868.	6.3	14
5	The Impact of Geography in Hepatocellular Carcinoma: A Retrospective Population Based Study. Current Oncology, 2021, 28, 396-404.	2.2	0
6	Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults. Current Oncology, 2021, 28, 523-548.	2.2	31
7	Impact of surveillance among patients with resected pancreatic cancer following adjuvant chemotherapy. Journal of Gastrointestinal Oncology, 2021, 12, 446-454.	1.4	0
8	Canadian Colorectal Cancer Screening Guidelines: Do They Need an Update Given Changing Incidence and Global Practice Patterns?. Current Oncology, 2021, 28, 1558-1570.	2.2	11
9	Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer. JNCI Cancer Spectrum, 2021, 5, pkab070.	2.9	4
10	Virtual Oncology Appointments during the Initial Wave of the COVID-19 Pandemic: An International Survey of Patient Perspectives. Current Oncology, 2021, 28, 671-677.	2.2	27
11	Current Attitudes toward Unfunded Cancer Therapies among Canadian Medical Oncologists. Current Oncology, 2021, 28, 4748-4755.	2.2	1
12	Current Oncology: A Multidisciplinary Medium for Clinical Oncology. Current Oncology, 2021, 28, 2-3.	2.2	0
13	A Hypothesis-Generating Study Using Electrophysiology to Examine Cognitive Function in Colon Cancer Patients. Archives of Clinical Neuropsychology, 2020, 35, 226-232.	0.5	2
14	Eligibility for Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 788-791.	1.3	1
15	Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases. Canadian Journal of Gastroenterology and Hepatology, 2020, 2020, 1-5.	1.9	6
16	Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer. JNCI Cancer Spectrum, 2020, 4, pkaa023.	2.9	36
17	Population-based Screening for BRAFV600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis. Clinical Cancer Research, 2020, 26, 4599-4605.	7.0	26
18	Integration of Whole-Genome Sequencing With Circulating Tumor DNA Analysis Captures Clonal Evolution and Tumor Heterogeneity in Non-V600 BRAF Mutant Colorectal Cancer. Clinical Colorectal Cancer, 2020, 19, 132-136.e3.	2.3	1

#	Article	IF	Citations
19	Health information seeking behaviors among individuals with young-onset and average-onset colorectal cancer: an international cross-sectional survey. Supportive Care in Cancer, 2020, 28, 6011-6021.	2.2	11
20	Trends in the epidemiology of young-onset colorectal cancer: a worldwide systematic review. BMC Cancer, 2020, 20, 288.	2.6	86
21	Real-world treatment attrition rates in advanced esophagogastric cancer. World Journal of Gastroenterology, 2020, 26, 6027-6036.	3.3	0
22	Current Oncology: A Multidisciplinary Medium for Clinical Oncology. Current Oncology, 2020, 28, 2-3.	2.2	0
23	The Evolving Treatment Landscape of Hepatocellular Carcinoma: More Choices, More Responsibility. Current Oncology, 2020, 27, 136-137.	2.2	1
24	NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2019, 25, 4674-4681.	7.0	121
25	Translating IDEA to Practice and Beyond: Managing Stage II and III Colon Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 226-235.	3.8	8
26	Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline. Journal of Clinical Oncology, 2019, 37, 1436-1447.	1.6	53
27	A phase II trial of the effect of perindopril on handâ€“foot skin reaction (HFSR) incidence and severity in patients receiving regorafenib for refractory mCRC. Cancer Chemotherapy and Pharmacology, 2019, 83, 411-417.	2.3	4
28	Outcomes and Characteristics of Patients Receiving Second-line Therapy for Advanced Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 196-201.	1.3	12
29	Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4) Tj ETQq1 1 0.784314 rgBT /O		
30	Real-world Outcomes Among Patients Treated With Gemcitabine-based Therapy Post-FOLFIRINOX Failure in Advanced Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 903-908.	1.3	8
31	Survival Impact of CAPOX Versus FOLFOX in the Adjuvant Treatment of Stage III Colon Cancer. Clinical Colorectal Cancer, 2018, 17, 156-163.	2.3	24
32	Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 263-270.	8.1	121
33	Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance). Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 696-703.	2.5	11
34	Utilization of capecitabine plus oxaliplatin and 5-fluorouracil/folinic acid plus oxaliplatin in the adjuvant treatment of stage IIB and stage III colon cancer: A multi-centre, retrospective, chart review study. Journal of Oncology Pharmacy Practice, 2018, 24, 501-506.	0.9	12
35	Beyond the Knife: The Evolving Nonsurgical Management of Oligometastatic Colorectal Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 209-219.	3.8	7
36	Type B lactic acidosis from fluorouracil in fluorouracil, oxaliplatin and leucovorin treatment for carcinoma of the colon in a hemodialysis patient. CKJ: Clinical Kidney Journal, 2018, 11, 786-787.	2.9	4

#	Article	IF	Citations
37	Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 552-554.	1.3	19
38	Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 507-511.	1.3	61
39	Prognostic utility of immune markers and validation of Immunoscore in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance). Annals of Oncology, 2017, 28, iii153.	1.2	1
40	Survival impact of CAPOX versus FOLFOX in the adjuvant treatment of stage III colon cancer.. Journal of Clinical Oncology, 2017, 35, 710-710.	1.6	0
41	Determinants of first-line treatment selection in advanced pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2017, 35, 468-468.	1.6	1
42	Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147. International Journal of Cancer, 2016, 139, 986-995.	5.1	16
43	Reasons for Underuse of Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer. Clinical Colorectal Cancer, 2016, 15, 179-185.	2.3	38
44	Effects of a Structured Exercise Program on Physical Activity and Fitness in Colon Cancer Survivors: One Year Feasibility Results from the CHALLENGE Trial. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 969-977.	2.5	75
45	Post-gemcitabine therapy for patients with advanced pancreatic cancer â€“ A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens. Cancer Treatment Reviews, 2016, 50, 142-147.	7.7	19
46	Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance). Oncologist, 2016, 21, 1509-1521.	3.7	33
47	PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy. Journal of Clinical Oncology, 2016, 34, 3914-3920.	1.6	210
48	Adjuvant chemotherapy use and outcomes of patients with highâ€risk versus lowâ€risk stage II colon cancer. Cancer, 2015, 121, 527-534.	4.1	118
49	Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer. Clinical Colorectal Cancer, 2015, 14, 262-268.e1.	2.3	17
50	Prognostic Value of Molecular Detection of Lymph Node Metastases After Curative Resection of Stage II Colon Cancer: A Systematic Pooled Data Analysis. Clinical Colorectal Cancer, 2015, 14, 99-105.	2.3	3
51	Effect of Delay in Adjuvant Oxaliplatin-Based Chemotherapy for Stage III Colon Cancer. Clinical Colorectal Cancer, 2015, 14, 25-30.	2.3	14
52	Effect of M1a and M1b Category in Metastatic Colorectal Cancer. Oncologist, 2014, 19, 720-726.	3.7	13
53	Adjuvant therapy for resected high-risk colon cancer: Current standards and controversies. Indian Journal of Medical and Paediatric Oncology, 2014, 35, 197.	0.2	4
54	Molecular Testing for Lymph Node Metastases as a Determinant of Colon Cancer Recurrence: Results from a Retrospective Multicenter Study. Clinical Cancer Research, 2014, 20, 4361-4369.	7.0	18

#	Article	IF	Citations
55	Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147. Clinical Colorectal Cancer, 2014, 13, 100-109.	2.3	41
56	Navigating later lines of treatment for advanced colorectal cancer â€“ Optimizing targeted biological therapies to improve outcomes. Cancer Treatment Reviews, 2014, 40, 1171-1181.	7.7	18
57	Update on the Colon Health and Life-Long Exercise Change Trial: A Phase III Study of the Impact of an Exercise Program on Disease-Free Survival in Colon Cancer Survivors. Current Colorectal Cancer Reports, 2014, 10, 321-328.	0.5	26
58	Neutropenia and Relative Dose Intensity on Adjuvant FOLFOX Chemotherapy Are Not Associated with Survival for Resected Colon Cancer. Journal of Gastrointestinal Cancer, 2014, 45, 460-465.	1.3	18
59	Relationship of ethnicity and overall survival in patients treated with sorafenib for advanced hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 2014, 5, 259-64.	1.4	10
60	Phase 2 trial of linifanib (ABTâ€869) in patients with unresectable or metastatic hepatocellular carcinoma. Cancer, 2013, 119, 380-387.	4.1	93
61	Body Mass Index and Body Surface Area and Their Associations with Outcomes in Stage II and III Colon Cancer. Journal of Gastrointestinal Cancer, 2013, 44, 203-210.	1.3	16
62	Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer. JAMA - Journal of the American Medical Association, 2012, 307, 1383.	7.4	412
63	Real-world Impact of Availability of Adjuvant Therapy on Outcomes in Patients With Resected Pancreatic Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 212-215.	1.3	4
64	A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer. Investigational New Drugs, 2012, 30, 779-786.	2.6	49
65	Evaluation of the prognostic value of guanylyl cyclase C (GCC) lymph node (LN) classification in patients with stage II colon cancer: A pooled analysis.. Journal of Clinical Oncology, 2012, 30, 443-443.	1.6	0
66	Survival for Metastatic Colorectal Cancer in the Bevacizumab Era: A Population-based Analysis. Clinical Colorectal Cancer, 2011, 10, 97-101.	2.3	26
67	Adjuvant Chemotherapy for Stage III Colon Cancer: Does Timing Matter?. Diseases of the Colon and Rectum, 2011, 54, 1082-1089.	1.3	47
68	Evaluation of Guanylyl Cyclase C Lymph Node Status for Colon Cancer Staging and Prognosis. Annals of Surgical Oncology, 2011, 18, 3261-3270.	1.5	30
69	Presentation and outcomes of patients aged 30Âyears and younger with colorectal cancer: a 20-year retrospective review. Medical Oncology, 2011, 28, 1058-1061.	2.5	21
70	Prognostic webâ€based models for stage II and III colon cancer. Cancer, 2011, 117, 4155-4165.	4.1	25
71	Validation of predictive models for germline mutations in DNA mismatch repair genes in colorectal cancer. International Journal of Cancer, 2010, 126, 930-939.	5.1	35
72	Primary Tumor Resection in Patients Presenting With Metastatic Colorectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 52-55.	1.3	26

#	Article	IF	Citations
73	Adjuvant Chemotherapy for Resected Stage II and III Colon Cancer: Comparison of Two Widely Used Prognostic Calculators. Seminars in Oncology, 2010, 37, 39-46.	2.2	21
74	Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer. Journal of Clinical Oncology, 2009, 27, 2231-2237.	1.6	611
75	Impact of Irinotecan and Oxaliplatin on Overall Survival in Patients With Metastatic Colorectal Cancer: A Population-Based Study. Journal of Oncology Practice, 2009, 5, 153-158.	2.5	13
76	Cetuximab, chemotherapy and KRAS status in mCRC. Nature Reviews Clinical Oncology, 2009, 6, 379-380.	27.6	8
77	Evolving end points for clinical trials in advanced colorectal cancer. Current Colorectal Cancer Reports, 2009, 5, 135-139.	0.5	1
78	Intraperitoneal Treatment for Peritoneal Mucinous Carcinomatosis of Appendiceal Origin After Operative Management. Annals of Surgery, 2009, 249, 588-595.	4.2	17
79	A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). Investigational New Drugs, 2008, 26, 265-272.	2.6	60
80	Individual data pooled analyses to improve understanding of adjuvant therapy in colon cancer: Review of the ACCENT collaborative group. Current Colorectal Cancer Reports, 2008, 4, 155-159.	0.5	1
81	Patterns of Diagnosis for Colorectal Cancer: Screening Detected vs. Symptomatic Presentation. Diseases of the Colon and Rectum, 2008, 51, 573-577.	1.3	10
82	Trends in Chemotherapy Utilization for Colorectal Cancer. Clinical Colorectal Cancer, 2008, 7, 386-389.	2.3	24
83	Adjuvant Therapy with Raltitrexed in Patients with Colorectal Cancer Intolerant of 5-Fluorouracil: British Columbia Cancer Agency Experience. Cancer Investigation, 2007, 25, 711-714.	1.3	14
84	Colorectal Cancer. Mayo Clinic Proceedings, 2007, 82, 114-129.	3.0	55
85	Capecitabine-Induced Cerebellar Toxicity. Clinical Colorectal Cancer, 2006, 6, 70-71.	2.3	32
86	Hepatic Dysfunction During and After Lymphoma Chemotherapy in Patients With Hepatitis C. Journal of Clinical Gastroenterology, 2006, 40, 636-638.	2.2	1
87	End Points for Adjuvant Therapy Trials: Has the Time Come to Accept Diseaseâ€Free Survival as a Surrogate End Point for Overall Survival?. Oncologist, 2006, 11, 624-629.	3.7	66
88	Colorectal cancer prevention: Is an ounce of prevention worth a pound of cure?. Seminars in Oncology, 2005, 32, 24-34.	2.2	49
89	New developments in therapy for metastatic colorectal cancer. Current Colorectal Cancer Reports, 2005, 1, 13-17.	0.5	0
90	Isolated Loss of PMS2 Expression in Colorectal Cancers: Frequency, Patient Age, and Familial Aggregation. Clinical Cancer Research, 2005, 11, 6466-6471.	7.0	54

#	Article	IF	Citations
91	Duration of adjuvant therapy for colorectal cancer: are we overtreating our patients?. Nature Clinical Practice Oncology, 2005, 2, 276-277.	4.3	0
92	Outcomes in Elderly Patients with Advanced Colorectal Cancer Treated with Capecitabine: A Population-Based Analysis. Clinical Colorectal Cancer, 2005, 5, 279-282.	2.3	38
93	Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?. Journal of Clinical Oncology, 2004, 22, 1797-1806.	1.6	913
94	Role of cyclooxygenase-2 in colorectal cancer. Cancer and Metastasis Reviews, 2004, 23, 63-75.	5.9	163
95	First-Line Treatment Strategies to Improve Survival in Patients with Advanced Colorectal Cancer. Drugs, 2004, 64, 27-44.	10.9	21
96	New targeted therapies in gastrointestinal cancers. Current Treatment Options in Oncology, 2003, 4, 393-403.	3.0	20
97	New developments in therapy for colorectal cancer. Current Oncology Reports, 2003, 5, 183-191.	4.0	5
98	Use of random skin biopsy to diagnose intravascular lymphoma presenting as fever of unknown origin. American Journal of Medicine, 2003, 114, 56-58.	1.5	71
99	Asian Ethnicityâ€“Related Differences in Gastric Cancer Presentation and Outcome Among Patients Treated at a Canadian Cancer Center. Journal of Clinical Oncology, 2003, 21, 2070-2076.	1.6	124
100	Paraneoplastic Sensory Neuronopathy and Spontaneous Regression of Small Cell Lung Cancer. Canadian Journal of Neurological Sciences, 2003, 30, 269-271.	0.5	54
101	Massive Bleeding on a Bladder Protectant. Archives of Internal Medicine, 2002, 162, 1644.	3.8	8
102	Obstacles to ResidentsÊ¼ Conducting Research and Predictors of Publication. Academic Medicine, 2001, 76, 477.	1.6	65